ID   MK08_HUMAN              Reviewed;         427 AA.
AC   P45983; B5BTZ5; B7ZLV4; D3DX88; D3DX92; Q15709; Q15712; Q15713; Q308M2;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   12-OCT-2022, entry version 230.
DE   RecName: Full=Mitogen-activated protein kinase 8;
DE            Short=MAP kinase 8;
DE            Short=MAPK 8;
DE            EC=2.7.11.24 {ECO:0000269|PubMed:10747973, ECO:0000269|PubMed:10856240, ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:16581800, ECO:0000269|PubMed:17296730, ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:8654373};
DE   AltName: Full=JNK-46;
DE   AltName: Full=Stress-activated protein kinase 1c;
DE            Short=SAPK1c;
DE   AltName: Full=Stress-activated protein kinase JNK1;
DE   AltName: Full=c-Jun N-terminal kinase 1;
GN   Name=MAPK8; Synonyms=JNK1, PRKM8, SAPK1, SAPK1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal brain;
RX   PubMed=8137421; DOI=10.1016/0092-8674(94)90380-8;
RA   Derijard B., Hibi M., Wu I.-H., Barrett T., Su B., Deng T., Karin M.,
RA   Davis R.J.;
RT   "JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and
RT   phosphorylates the c-Jun activation domain.";
RL   Cell 76:1025-1037(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND CATALYTIC ACTIVITY.
RC   TISSUE=Brain;
RX   PubMed=8654373; DOI=10.1002/j.1460-2075.1996.tb00636.x;
RA   Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B.,
RA   Davis R.J.;
RT   "Selective interaction of JNK protein kinase isoforms with transcription
RT   factors.";
RL   EMBO J. 15:2760-2770(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RA   Lin L., Nong W., Zhou G., Ke R., Shen C., Zhong G., Zheng Z., Liang M.,
RA   Tang Z., Huang B., Li H., Yang S.;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   MUTAGENESIS OF THR-183 AND TYR-185.
RX   PubMed=7839144; DOI=10.1126/science.7839144;
RA   Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J.,
RA   Davis R.J.;
RT   "Independent human MAP-kinase signal transduction pathways defined by MEK
RT   and MKK isoforms.";
RL   Science 267:682-685(1995).
RN   [9]
RP   PHOSPHORYLATION AT THR-183 AND TYR-185, REGULATION BY MAP2K4 AND MAP2K7,
RP   CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=11062067; DOI=10.1042/bj3520145;
RA   Fleming Y., Armstrong C.G., Morrice N., Paterson A., Goedert M., Cohen P.;
RT   "Synergistic activation of stress-activated protein kinase 1/c-Jun N-
RT   terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase
RT   kinase 4 (MKK4) and MKK7.";
RL   Biochem. J. 352:145-154(2000).
RN   [10]
RP   INTERACTION WITH MECOM, AND CATALYTIC ACTIVITY.
RX   PubMed=10856240; DOI=10.1093/emboj/19.12.2958;
RA   Kurokawa M., Mitani K., Yamagata T., Takahashi T., Izutsu K., Ogawa S.,
RA   Moriguchi T., Nishida E., Yazaki Y., Hirai H.;
RT   "The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents
RT   stress-induced cell death.";
RL   EMBO J. 19:2958-2968(2000).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF HSF1, CATALYTIC ACTIVITY, AND INTERACTION
RP   WITH HSF1.
RX   PubMed=10747973; DOI=10.1074/jbc.m000958200;
RA   Dai R., Frejtag W., He B., Zhang Y., Mivechi N.F.;
RT   "c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock
RT   factor-1 suppress its transcriptional activity.";
RL   J. Biol. Chem. 275:18210-18218(2000).
RN   [12]
RP   INTERACTION WITH WWOX AND TP53.
RX   PubMed=12514174; DOI=10.1074/jbc.m208373200;
RA   Chang N.-S., Doherty J., Ensign A.;
RT   "JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1)
RT   and inhibits WOX1-mediated apoptosis.";
RL   J. Biol. Chem. 278:9195-9202(2003).
RN   [13]
RP   INTERACTION WITH SPAG9.
RX   PubMed=15693750; DOI=10.1042/bj20041577;
RA   Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S., Herr J.C.,
RA   Okumura K., Hasegawa A., Koyama K., Suri A.;
RT   "Characterization of a novel human sperm-associated antigen 9 (SPAG9)
RT   having structural homology with c-Jun N-terminal kinase-interacting
RT   protein.";
RL   Biochem. J. 389:73-82(2005).
RN   [14]
RP   FUNCTION, INTERACTION WITH HSF4, AND CATALYTIC ACTIVITY.
RX   PubMed=16581800; DOI=10.1128/mcb.26.8.3282-3294.2006;
RA   Hu Y., Mivechi N.F.;
RT   "Association and regulation of heat shock transcription factor 4b with both
RT   extracellular signal-regulated kinase mitogen-activated protein kinase and
RT   dual-specificity tyrosine phosphatase DUSP26.";
RL   Mol. Cell. Biol. 26:3282-3294(2006).
RN   [15]
RP   INTERACTION WITH NFATC4, AND CATALYTIC ACTIVITY.
RX   PubMed=17875713; DOI=10.1158/0008-5472.can-06-4788;
RA   Yao K., Cho Y.-Y., Bergen H.R. III, Madden B.J., Choi B.Y., Ma W.-Y.,
RA   Bode A.M., Dong Z.;
RT   "Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1
RT   induced cell transformation.";
RL   Cancer Res. 67:8725-8735(2007).
RN   [16]
RP   INTERACTION WITH GRIPAP1, AND PHOSPHORYLATION BY MAP3K1.
RX   PubMed=17761173; DOI=10.1016/j.febslet.2007.08.008;
RA   Ye B., Yu W.P., Thomas G.M., Huganir R.L.;
RT   "GRASP-1 is a neuronal scaffold protein for the JNK signaling pathway.";
RL   FEBS Lett. 581:4403-4410(2007).
RN   [17]
RP   PHOSPHORYLATION BY TAOK2.
RX   PubMed=17158878; DOI=10.1074/jbc.m608336200;
RA   Zihni C., Mitsopoulos C., Tavares I.A., Baum B., Ridley A.J., Morris J.D.;
RT   "Prostate-derived sterile 20-like kinase 1-alpha induces apoptosis.
RT   JNK- and caspase-dependent nuclear localization is a requirement for
RT   membrane blebbing.";
RL   J. Biol. Chem. 282:6484-6493(2007).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF ELK1, AND CATALYTIC ACTIVITY.
RX   PubMed=17296730; DOI=10.1128/mcb.02276-06;
RA   Zhang L., Yang S.H., Sharrocks A.D.;
RT   "Rev7/MAD2B links c-Jun N-terminal protein kinase pathway signaling to
RT   activation of the transcription factor Elk-1.";
RL   Mol. Cell. Biol. 27:2861-2869(2007).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF JDP2, AND CATALYTIC ACTIVITY.
RX   PubMed=18307971; DOI=10.1016/j.ab.2008.01.038;
RA   Murata T., Shinozuka Y., Obata Y., Yokoyama K.K.;
RT   "Phosphorylation of two eukaryotic transcription factors, Jun dimerization
RT   protein 2 and activation transcription factor 2, in Escherichia coli by Jun
RT   N-terminal kinase 1.";
RL   Anal. Biochem. 376:115-121(2008).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF BCL2.
RX   PubMed=18570871; DOI=10.1016/j.molcel.2008.06.001;
RA   Wei Y., Pattingre S., Sinha S., Bassik M., Levine B.;
RT   "JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced
RT   autophagy.";
RL   Mol. Cell 30:678-688(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377 (ISOFORMS 1 AND 3),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301 (ISOFORM 5), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   INTERACTION WITH SERPINB3, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=19166818; DOI=10.1016/j.bbrc.2009.01.057;
RA   Zheng B., Matoba Y., Kumagai T., Katagiri C., Hibino T., Sugiyama M.;
RT   "Crystal structure of SCCA1 and insight about the interaction with JNK1.";
RL   Biochem. Biophys. Res. Commun. 380:143-147(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377 (ISOFORMS 1 AND 3),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301 (ISOFORM 5), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF SIRT1, AND CATALYTIC ACTIVITY.
RX   PubMed=20027304; DOI=10.1371/journal.pone.0008414;
RA   Nasrin N., Kaushik V.K., Fortier E., Wall D., Pearson K.J., de Cabo R.,
RA   Bordone L.;
RT   "JNK1 phosphorylates SIRT1 and promotes its enzymatic activity.";
RL   PLoS ONE 4:E8414-E8414(2009).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF YAP1, AND CATALYTIC ACTIVITY.
RX   PubMed=21364637; DOI=10.1038/cddis.2010.7;
RA   Tomlinson V., Gudmundsdottir K., Luong P., Leung K.Y., Knebel A., Basu S.;
RT   "JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis.";
RL   Cell Death Dis. 1:E29-E29(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   INTERACTION WITH PIN1, AND CATALYTIC ACTIVITY.
RX   PubMed=21660049; DOI=10.1038/cdd.2011.82;
RA   Park J.E., Lee J.A., Park S.G., Lee D.H., Kim S.J., Kim H.J., Uchida C.,
RA   Uchida T., Park B.C., Cho S.;
RT   "A critical step for JNK activation: isomerization by the prolyl isomerase
RT   Pin1.";
RL   Cell Death Differ. 19:153-161(2012).
RN   [29]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22441692; DOI=10.1038/embor.2012.37;
RA   Yoshitane H., Honma S., Imamura K., Nakajima H., Nishide S.Y., Ono D.,
RA   Kiyota H., Shinozaki N., Matsuki H., Wada N., Doi H., Hamada T., Honma K.,
RA   Fukada Y.;
RT   "JNK regulates the photic response of the mammalian circadian clock.";
RL   EMBO Rep. 13:455-461(2012).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF BAD, AND CATALYTIC ACTIVITY.
RX   PubMed=21095239; DOI=10.1016/j.biocel.2010.11.011;
RA   Deng H., Zhang J., Yoon T., Song D., Li D., Lin A.;
RT   "Phosphorylation of Bcl-associated death protein (Bad) by erythropoietin-
RT   activated c-Jun N-terminal protein kinase 1 contributes to survival of
RT   erythropoietin-dependent cells.";
RL   Int. J. Biochem. Cell Biol. 43:409-415(2011).
RN   [31]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21148294; DOI=10.1091/mbc.e10-06-0492;
RA   Wang J., Tang R., Lv M., Wang Q., Zhang X., Guo Y., Chang H., Qiao C.,
RA   Xiao H., Li X., Li Y., Shen B., Zhang J.;
RT   "Defective anchoring of JNK1 in the cytoplasm by MKK7 in Jurkat cells is
RT   associated with resistance to Fas-mediated apoptosis.";
RL   Mol. Biol. Cell 22:117-127(2011).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF CDT1, AND CATALYTIC ACTIVITY.
RX   PubMed=21856198; DOI=10.1016/j.molcel.2011.06.021;
RA   Miotto B., Struhl K.;
RT   "JNK1 phosphorylation of Cdt1 inhibits recruitment of HBO1 histone
RT   acetylase and blocks replication licensing in response to stress.";
RL   Mol. Cell 44:62-71(2011).
RN   [33]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-55.
RX   PubMed=22966201; DOI=10.1128/mcb.00544-12;
RA   Cargnello M., Tcherkezian J., Dorn J.F., Huttlin E.L., Maddox P.S.,
RA   Gygi S.P., Roux P.P.;
RT   "Phosphorylation of the eukaryotic translation initiation factor 4E-
RT   transporter (4E-T) by c-Jun N-terminal kinase promotes stress-dependent P-
RT   body assembly.";
RL   Mol. Cell. Biol. 32:4572-4584(2012).
RN   [34]
RP   FUNCTION.
RX   PubMed=22327296; DOI=10.1038/nature10806;
RA   Huang J., Gurung B., Wan B., Matkar S., Veniaminova N.A., Wan K.,
RA   Merchant J.L., Hua X., Lei M.;
RT   "The same pocket in menin binds both MLL and JUND but has opposite effects
RT   on transcription.";
RL   Nature 482:542-546(2012).
RN   [35]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=27568560; DOI=10.1016/j.celrep.2016.08.006;
RA   Van Meter M., Simon M., Tombline G., May A., Morello T.D., Hubbard B.P.,
RA   Bredbenner K., Park R., Sinclair D.A., Bohr V.A., Gorbunova V.,
RA   Seluanov A.;
RT   "JNK phosphorylates SIRT6 to stimulate DNA double-strand break repair in
RT   response to oxidative stress by recruiting PARP1 to DNA Breaks.";
RL   Cell Rep. 16:2641-2650(2016).
RN   [36]
RP   SUBCELLULAR LOCATION.
RX   PubMed=30878395; DOI=10.1016/j.yjmcc.2019.03.005;
RA   Li C., Li J., Xue K., Zhang J., Wang C., Zhang Q., Chen X., Gao C., Yu X.,
RA   Sun L.;
RT   "MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3
RT   after myocardial infarction.";
RL   J. Mol. Cell. Cardiol. 129:281-292(2019).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 1-363, AND CATALYTIC ACTIVITY.
RX   PubMed=15141161; DOI=10.1038/sj.emboj.7600212;
RA   Heo Y.S., Kim S.K., Seo C.I., Kim Y.K., Sung B.J., Lee H.S., Lee J.I.,
RA   Park S.Y., Kim J.H., Hwang K.Y., Hyun Y.L., Jeon Y.H., Ro S., Cho J.M.,
RA   Lee T.G., Yang C.H.;
RT   "Structural basis for the selective inhibition of JNK1 by the scaffolding
RT   protein JIP1 and SP600125.";
RL   EMBO J. 23:2185-2195(2004).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-171 AND ARG-177.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in various processes
CC       such as cell proliferation, differentiation, migration, transformation
CC       and programmed cell death. Extracellular stimuli such as pro-
CC       inflammatory cytokines or physical stress stimulate the stress-
CC       activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling
CC       pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and
CC       MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1
CC       phosphorylates a number of transcription factors, primarily components
CC       of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1
CC       transcriptional activity (PubMed:18307971). Phosphorylates the
CC       replication licensing factor CDT1, inhibiting the interaction between
CC       CDT1 and the histone H4 acetylase HBO1 to replication origins
CC       (PubMed:21856198). Loss of this interaction abrogates the acetylation
CC       required for replication initiation (PubMed:21856198). Promotes
CC       stressed cell apoptosis by phosphorylating key regulatory factors
CC       including p53/TP53 and Yes-associates protein YAP1 (PubMed:21364637).
CC       In T-cells, MAPK8 and MAPK9 are required for polarized differentiation
CC       of T-helper cells into Th1 cells. Contributes to the survival of
CC       erythroid cells by phosphorylating the antagonist of cell death BAD
CC       upon EPO stimulation (PubMed:21095239). Mediates starvation-induced
CC       BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation
CC       of autophagy (PubMed:18570871). Phosphorylates STMN2 and hence
CC       regulates microtubule dynamics, controlling neurite elongation in
CC       cortical neurons (By similarity). In the developing brain, through its
CC       cytoplasmic activity on STMN2, negatively regulates the rate of exit
CC       from multipolar stage and of radial migration from the ventricular zone
CC       (By similarity). Phosphorylates several other substrates including heat
CC       shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3
CC       ligase ITCH (PubMed:20027304, PubMed:16581800, PubMed:17296730).
CC       Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in
CC       the regulation of the circadian clock (PubMed:22441692). Phosphorylates
CC       the heat shock transcription factor HSF1, suppressing HSF1-induced
CC       transcriptional activity (PubMed:10747973). Phosphorylates POU5F1,
CC       which results in the inhibition of POU5F1's transcriptional activity
CC       and enhances its proteosomal degradation (By similarity).
CC       Phosphorylates JUND and this phosphorylation is inhibited in the
CC       presence of MEN1 (PubMed:22327296). In neurons, phosphorylates SYT4
CC       which captures neuronal dense core vesicles at synapses (By
CC       similarity). Phosphorylates EIF4ENIF1/4-ET in response to oxidative
CC       stress, promoting P-body assembly (PubMed:22966201). Phosphorylates
CC       SIRT6 in response to oxidative stress, stimulating its mono-ADP-
CC       ribosyltransferase activity (PubMed:27568560).
CC       {ECO:0000250|UniProtKB:P49185, ECO:0000250|UniProtKB:Q91Y86,
CC       ECO:0000269|PubMed:10747973, ECO:0000269|PubMed:16581800,
CC       ECO:0000269|PubMed:17296730, ECO:0000269|PubMed:18307971,
CC       ECO:0000269|PubMed:18570871, ECO:0000269|PubMed:20027304,
CC       ECO:0000269|PubMed:21095239, ECO:0000269|PubMed:21364637,
CC       ECO:0000269|PubMed:21856198, ECO:0000269|PubMed:22327296,
CC       ECO:0000269|PubMed:22441692, ECO:0000269|PubMed:22966201,
CC       ECO:0000269|PubMed:27568560}.
CC   -!- FUNCTION: JNK1 isoforms display different binding patterns: beta-1
CC       preferentially binds to c-Jun, whereas alpha-1, alpha-2, and beta-2
CC       have a similar low level of binding to both c-Jun or ATF2. However,
CC       there is no correlation between binding and phosphorylation, which is
CC       achieved at about the same efficiency by all isoforms.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC         Evidence={ECO:0000269|PubMed:10747973, ECO:0000269|PubMed:10856240,
CC         ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15141161,
CC         ECO:0000269|PubMed:16581800, ECO:0000269|PubMed:17296730,
CC         ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:18307971,
CC         ECO:0000269|PubMed:19166818, ECO:0000269|PubMed:20027304,
CC         ECO:0000269|PubMed:21095239, ECO:0000269|PubMed:21364637,
CC         ECO:0000269|PubMed:21660049, ECO:0000269|PubMed:21856198,
CC         ECO:0000269|PubMed:22441692, ECO:0000269|PubMed:22966201,
CC         ECO:0000269|PubMed:27568560, ECO:0000269|PubMed:8654373};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24; Evidence={ECO:0000269|PubMed:10747973,
CC         ECO:0000269|PubMed:10856240, ECO:0000269|PubMed:11062067,
CC         ECO:0000269|PubMed:15141161, ECO:0000269|PubMed:16581800,
CC         ECO:0000269|PubMed:17296730, ECO:0000269|PubMed:17875713,
CC         ECO:0000269|PubMed:18307971, ECO:0000269|PubMed:19166818,
CC         ECO:0000269|PubMed:20027304, ECO:0000269|PubMed:21095239,
CC         ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:21660049,
CC         ECO:0000269|PubMed:21856198, ECO:0000269|PubMed:22441692,
CC         ECO:0000269|PubMed:8654373};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11062067};
CC   -!- ACTIVITY REGULATION: Activated by threonine and tyrosine
CC       phosphorylation by either of two dual specificity kinases, MAP2K4 and
CC       MAP2K7. MAP2K4 shows a strong preference for Tyr-185 while MAP2K7
CC       phosphorylates Tyr-183 preferentially. Inhibited by dual specificity
CC       phosphatases, such as DUSP1. Inhibited by SERPINB3.
CC       {ECO:0000269|PubMed:19166818}.
CC   -!- SUBUNIT: Forms a complex with MAPK8IP1 and ARHGEF28 (By similarity).
CC       Found in a complex with SH3RF1, RAC1, MAP3K11/MLK3, MAP2K7/MKK7 and
CC       MAPK8IP1/JIP1. Found in a complex with SH3RF1, RAC2, MAP3K7/TAK1,
CC       MAP2K7/MKK7, MAPK8IP1/JIP1 and MAPK9/JNK2 (By similarity). Binds to at
CC       least four scaffolding proteins, MAPK8IP1/JIP-1, MAPK8IP2/JIP-2,
CC       MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4 (PubMed:15693750). These
CC       proteins also bind other components of the JNK signaling pathway.
CC       Interacts with TP53 and WWOX (PubMed:12514174). Interacts with JAMP (By
CC       similarity). Interacts with HSF1 (via D domain and preferentially with
CC       hyperphosphorylated form); this interaction occurs under both normal
CC       growth conditions and immediately upon heat shock (PubMed:10747973).
CC       Interacts (phosphorylated form) with NFE2; the interaction
CC       phosphorylates NFE2 in undifferentiated cells (By similarity).
CC       Interacts with NFATC4 (PubMed:17875713). Interacts with MECOM;
CC       regulates JNK signaling (PubMed:10856240). Interacts with PIN1; this
CC       interaction mediates MAPK8 conformational changes leading to the
CC       binding of MAPK8 to its substrates (PubMed:21660049). Interacts with
CC       GRIPAP1 (PubMed:17761173). Interacts with POU5F1; phosphorylates POU5F1
CC       at 'Ser-355'. Interacts with STMN2, STMN3 and STMN4 (By similarity).
CC       Interacts with HSF4 (PubMed:16581800). {ECO:0000250|UniProtKB:P49185,
CC       ECO:0000250|UniProtKB:Q91Y86, ECO:0000269|PubMed:10747973,
CC       ECO:0000269|PubMed:10856240, ECO:0000269|PubMed:12514174,
CC       ECO:0000269|PubMed:15693750, ECO:0000269|PubMed:16581800,
CC       ECO:0000269|PubMed:17761173, ECO:0000269|PubMed:17875713,
CC       ECO:0000269|PubMed:19166818, ECO:0000269|PubMed:21660049}.
CC   -!- INTERACTION:
CC       P45983; P22681: CBL; NbExp=2; IntAct=EBI-286483, EBI-518228;
CC       P45983; P16104: H2AX; NbExp=3; IntAct=EBI-286483, EBI-494830;
CC       P45983; P05412: JUN; NbExp=5; IntAct=EBI-286483, EBI-852823;
CC       P45983; P45985: MAP2K4; NbExp=2; IntAct=EBI-286483, EBI-447868;
CC       P45983; O14733-2: MAP2K7; NbExp=3; IntAct=EBI-286483, EBI-492627;
CC       P45983; Q9UQF2: MAPK8IP1; NbExp=7; IntAct=EBI-286483, EBI-78404;
CC       P45983; P27986: PIK3R1; NbExp=6; IntAct=EBI-286483, EBI-79464;
CC       P45983; Q8N122: RPTOR; NbExp=6; IntAct=EBI-286483, EBI-1567928;
CC       P45983; Q9WVI9-1: Mapk8ip1; Xeno; NbExp=2; IntAct=EBI-286483, EBI-288461;
CC       P45983-1; P05412: JUN; NbExp=2; IntAct=EBI-288687, EBI-852823;
CC       P45983-4; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-18121963, EBI-3443946;
CC       P45983-4; Q9BY84: DUSP16; NbExp=3; IntAct=EBI-18121963, EBI-3443956;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21148294}. Nucleus
CC       {ECO:0000269|PubMed:21148294, ECO:0000269|PubMed:30878395}. Synapse
CC       {ECO:0000250|UniProtKB:P49185}. Note=In the cortical neurons,
CC       predominantly cytoplasmic and associated with the Golgi apparatus and
CC       endosomal fraction. Increased neuronal activity increases
CC       phosphorylated form at synapses (By similarity). Colocalizes with
CC       POU5F1 in the nucleus. {ECO:0000250|UniProtKB:P49185,
CC       ECO:0000250|UniProtKB:Q91Y86}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=2; Synonyms=JNK1-alpha-2;
CC         IsoId=P45983-1; Sequence=Displayed;
CC       Name=1; Synonyms=JNK1-alpha-1;
CC         IsoId=P45983-2; Sequence=VSP_004833;
CC       Name=3; Synonyms=JNK1-beta-1;
CC         IsoId=P45983-3; Sequence=VSP_004831, VSP_004832, VSP_004833;
CC       Name=4; Synonyms=JNK1-beta-2;
CC         IsoId=P45983-4; Sequence=VSP_004831, VSP_004832;
CC       Name=5;
CC         IsoId=P45983-5; Sequence=VSP_054554, VSP_004833;
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and MAP2K4,
CC       which activates the enzyme (PubMed:11062067). Phosphorylated by TAOK2
CC       (PubMed:17158878). May be phosphorylated at Thr-183 and Tyr-185 by
CC       MAP3K1/MEKK1 (PubMed:17761173). Phosphorylated form is more
CC       concentrated at synapses than none-phosphorylated (By similarity).
CC       {ECO:0000250|UniProtKB:P49185, ECO:0000269|PubMed:11062067,
CC       ECO:0000269|PubMed:17158878, ECO:0000269|PubMed:17761173}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JNK1ID196.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=C-Jun N-terminal kinases entry;
CC       URL="https://en.wikipedia.org/wiki/C-Jun_N-terminal_kinases";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L26318; AAA36131.1; -; mRNA.
DR   EMBL; U34822; AAC50607.1; -; mRNA.
DR   EMBL; U35004; AAC50610.1; -; mRNA.
DR   EMBL; U35005; AAC50611.1; -; mRNA.
DR   EMBL; DQ234352; ABB29981.1; -; mRNA.
DR   EMBL; AC016397; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC074325; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB451231; BAG70045.1; -; mRNA.
DR   EMBL; CH471187; EAW93132.1; -; Genomic_DNA.
DR   EMBL; CH471187; EAW93129.1; -; Genomic_DNA.
DR   EMBL; CH471187; EAW93130.1; -; Genomic_DNA.
DR   EMBL; CH471187; EAW93133.1; -; Genomic_DNA.
DR   EMBL; CH471187; EAW93134.1; -; Genomic_DNA.
DR   EMBL; CH471187; EAW93136.1; -; Genomic_DNA.
DR   EMBL; BC144063; AAI44064.1; -; mRNA.
DR   CCDS; CCDS60527.1; -. [P45983-5]
DR   CCDS; CCDS7223.1; -. [P45983-4]
DR   CCDS; CCDS7224.1; -. [P45983-1]
DR   CCDS; CCDS7225.1; -. [P45983-2]
DR   CCDS; CCDS7226.1; -. [P45983-3]
DR   PIR; S71097; S71097.
DR   PIR; S71099; S71099.
DR   RefSeq; NP_001265476.1; NM_001278547.1. [P45983-4]
DR   RefSeq; NP_001265477.1; NM_001278548.1. [P45983-5]
DR   RefSeq; NP_001310231.1; NM_001323302.1. [P45983-2]
DR   RefSeq; NP_001310250.1; NM_001323321.1. [P45983-3]
DR   RefSeq; NP_001310251.1; NM_001323322.1. [P45983-4]
DR   RefSeq; NP_001310252.1; NM_001323323.1. [P45983-4]
DR   RefSeq; NP_001310253.1; NM_001323324.1. [P45983-2]
DR   RefSeq; NP_001310254.1; NM_001323325.1. [P45983-3]
DR   RefSeq; NP_001310255.1; NM_001323326.1. [P45983-2]
DR   RefSeq; NP_001310256.1; NM_001323327.1. [P45983-2]
DR   RefSeq; NP_001310257.1; NM_001323328.1. [P45983-1]
DR   RefSeq; NP_001310258.1; NM_001323329.1. [P45983-1]
DR   RefSeq; NP_001310259.1; NM_001323330.1. [P45983-4]
DR   RefSeq; NP_001310260.1; NM_001323331.1. [P45983-1]
DR   RefSeq; NP_620634.1; NM_139046.3. [P45983-3]
DR   RefSeq; NP_620637.1; NM_139049.3. [P45983-1]
DR   PDB; 1UKH; X-ray; 2.35 A; A=1-363.
DR   PDB; 1UKI; X-ray; 2.70 A; A=1-363.
DR   PDB; 2G01; X-ray; 3.50 A; A/B=1-364.
DR   PDB; 2GMX; X-ray; 3.50 A; A/B=1-364.
DR   PDB; 2H96; X-ray; 3.00 A; A/B=1-364.
DR   PDB; 2NO3; X-ray; 3.20 A; A/B=1-364.
DR   PDB; 2XRW; X-ray; 1.33 A; A=2-364.
DR   PDB; 2XS0; X-ray; 2.60 A; A=1-379.
DR   PDB; 3ELJ; X-ray; 1.80 A; A=1-364.
DR   PDB; 3O17; X-ray; 3.00 A; A/B=1-364.
DR   PDB; 3O2M; X-ray; 2.70 A; A/B=1-364.
DR   PDB; 3PZE; X-ray; 2.00 A; A=7-364.
DR   PDB; 3V3V; X-ray; 2.70 A; A=1-366.
DR   PDB; 3VUD; X-ray; 3.50 A; A=1-364.
DR   PDB; 3VUG; X-ray; 3.24 A; A=1-364.
DR   PDB; 3VUH; X-ray; 2.70 A; A=1-364.
DR   PDB; 3VUI; X-ray; 2.80 A; A=1-364.
DR   PDB; 3VUK; X-ray; 2.95 A; A=1-364.
DR   PDB; 3VUL; X-ray; 2.81 A; A=1-364.
DR   PDB; 3VUM; X-ray; 2.69 A; A=1-364.
DR   PDB; 4AWI; X-ray; 1.91 A; A=1-364.
DR   PDB; 4E73; X-ray; 2.27 A; A=1-363.
DR   PDB; 4G1W; X-ray; 2.45 A; A=1-363.
DR   PDB; 4HYS; X-ray; 2.42 A; A=1-363.
DR   PDB; 4HYU; X-ray; 2.15 A; A=1-363.
DR   PDB; 4IZY; X-ray; 2.30 A; A=1-363.
DR   PDB; 4L7F; X-ray; 1.95 A; A=7-362.
DR   PDB; 4QTD; X-ray; 1.50 A; A=1-363.
DR   PDB; 4UX9; X-ray; 2.34 A; A/B/C/D=1-364.
DR   PDB; 4YR8; X-ray; 2.40 A; A/C/E/F=1-363.
DR   PDB; 5LW1; X-ray; 3.20 A; B/E/H=2-363.
DR   PDB; 6F5E; X-ray; 2.70 A; B=2-363.
DR   PDB; 6ZR5; X-ray; 2.70 A; A/B=1-364.
DR   PDBsum; 1UKH; -.
DR   PDBsum; 1UKI; -.
DR   PDBsum; 2G01; -.
DR   PDBsum; 2GMX; -.
DR   PDBsum; 2H96; -.
DR   PDBsum; 2NO3; -.
DR   PDBsum; 2XRW; -.
DR   PDBsum; 2XS0; -.
DR   PDBsum; 3ELJ; -.
DR   PDBsum; 3O17; -.
DR   PDBsum; 3O2M; -.
DR   PDBsum; 3PZE; -.
DR   PDBsum; 3V3V; -.
DR   PDBsum; 3VUD; -.
DR   PDBsum; 3VUG; -.
DR   PDBsum; 3VUH; -.
DR   PDBsum; 3VUI; -.
DR   PDBsum; 3VUK; -.
DR   PDBsum; 3VUL; -.
DR   PDBsum; 3VUM; -.
DR   PDBsum; 4AWI; -.
DR   PDBsum; 4E73; -.
DR   PDBsum; 4G1W; -.
DR   PDBsum; 4HYS; -.
DR   PDBsum; 4HYU; -.
DR   PDBsum; 4IZY; -.
DR   PDBsum; 4L7F; -.
DR   PDBsum; 4QTD; -.
DR   PDBsum; 4UX9; -.
DR   PDBsum; 4YR8; -.
DR   PDBsum; 5LW1; -.
DR   PDBsum; 6F5E; -.
DR   PDBsum; 6ZR5; -.
DR   AlphaFoldDB; P45983; -.
DR   SMR; P45983; -.
DR   BioGRID; 111585; 223.
DR   DIP; DIP-249N; -.
DR   ELM; P45983; -.
DR   IntAct; P45983; 113.
DR   MINT; P45983; -.
DR   STRING; 9606.ENSP00000378974; -.
DR   BindingDB; P45983; -.
DR   ChEMBL; CHEMBL2276; -.
DR   DrugBank; DB07268; 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE.
DR   DrugBank; DB07845; 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide.
DR   DrugBank; DB07276; 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE.
DR   DrugBank; DB07218; 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE.
DR   DrugBank; DB15624; Halicin.
DR   DrugBank; DB01017; Minocycline.
DR   DrugBank; DB07272; N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE.
DR   DrugBank; DB01782; Pyrazolanthrone.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugCentral; P45983; -.
DR   GuidetoPHARMACOLOGY; 1496; -.
DR   iPTMnet; P45983; -.
DR   PhosphoSitePlus; P45983; -.
DR   BioMuta; MAPK8; -.
DR   DMDM; 2507195; -.
DR   CPTAC; CPTAC-889; -.
DR   CPTAC; CPTAC-890; -.
DR   CPTAC; CPTAC-891; -.
DR   CPTAC; CPTAC-892; -.
DR   EPD; P45983; -.
DR   jPOST; P45983; -.
DR   MassIVE; P45983; -.
DR   MaxQB; P45983; -.
DR   PaxDb; P45983; -.
DR   PeptideAtlas; P45983; -.
DR   PRIDE; P45983; -.
DR   ProteomicsDB; 55694; -. [P45983-1]
DR   ProteomicsDB; 55695; -. [P45983-2]
DR   ProteomicsDB; 55696; -. [P45983-3]
DR   ProteomicsDB; 55697; -. [P45983-4]
DR   ProteomicsDB; 61569; -.
DR   Antibodypedia; 3846; 1690 antibodies from 46 providers.
DR   CPTC; P45983; 1 antibody.
DR   DNASU; 5599; -.
DR   Ensembl; ENST00000360332.7; ENSP00000353483.4; ENSG00000107643.17. [P45983-5]
DR   Ensembl; ENST00000374176.8; ENSP00000363291.4; ENSG00000107643.17. [P45983-4]
DR   Ensembl; ENST00000374179.8; ENSP00000363294.3; ENSG00000107643.17. [P45983-3]
DR   Ensembl; ENST00000374182.7; ENSP00000363297.3; ENSG00000107643.17. [P45983-2]
DR   Ensembl; ENST00000374189.6; ENSP00000363304.1; ENSG00000107643.17. [P45983-1]
DR   Ensembl; ENST00000395611.7; ENSP00000378974.4; ENSG00000107643.17. [P45983-4]
DR   GeneID; 5599; -.
DR   KEGG; hsa:5599; -.
DR   MANE-Select; ENST00000374189.6; ENSP00000363304.1; NM_001323329.2; NP_001310258.1.
DR   UCSC; uc001jgm.5; human. [P45983-1]
DR   CTD; 5599; -.
DR   DisGeNET; 5599; -.
DR   GeneCards; MAPK8; -.
DR   HGNC; HGNC:6881; MAPK8.
DR   HPA; ENSG00000107643; Low tissue specificity.
DR   MIM; 601158; gene.
DR   neXtProt; NX_P45983; -.
DR   OpenTargets; ENSG00000107643; -.
DR   PharmGKB; PA283; -.
DR   VEuPathDB; HostDB:ENSG00000107643; -.
DR   eggNOG; KOG0665; Eukaryota.
DR   GeneTree; ENSGT00940000153692; -.
DR   InParanoid; P45983; -.
DR   OMA; HADSEHN; -.
DR   OrthoDB; 741207at2759; -.
DR   PhylomeDB; P45983; -.
DR   TreeFam; TF105100; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   PathwayCommons; P45983; -.
DR   Reactome; R-HSA-111446; Activation of BIM and translocation to mitochondria.
DR   Reactome; R-HSA-139910; Activation of BMF and translocation to mitochondria.
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-205043; NRIF signals cell death from the nucleus.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-376172; DSCAM interactions.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-9007892; Interleukin-38 signaling.
DR   Reactome; R-HSA-9673324; WNT5:FZD7-mediated leishmania damping.
DR   SignaLink; P45983; -.
DR   SIGNOR; P45983; -.
DR   BioGRID-ORCS; 5599; 21 hits in 1118 CRISPR screens.
DR   ChiTaRS; MAPK8; human.
DR   EvolutionaryTrace; P45983; -.
DR   GeneWiki; MAPK8; -.
DR   GenomeRNAi; 5599; -.
DR   Pharos; P45983; Tchem.
DR   PRO; PR:P45983; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P45983; protein.
DR   Bgee; ENSG00000107643; Expressed in cortical plate and 181 other tissues.
DR   ExpressionAtlas; P45983; baseline and differential.
DR   Genevisible; P45983; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0030424; C:axon; ISS:ARUK-UCL.
DR   GO; GO:0097441; C:basal dendrite; ISS:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0004705; F:JUN kinase activity; IDA:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:UniProtKB.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IDA:CAFA.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:MGI.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0090398; P:cellular senescence; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0007258; P:JUN phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0031343; P:positive regulation of cell killing; TAS:Reactome.
DR   GO; GO:0031281; P:positive regulation of cyclase activity; IMP:CACAO.
DR   GO; GO:0090045; P:positive regulation of deacetylase activity; IMP:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IMP:CACAO.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:CAFA.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:1902595; P:regulation of DNA replication origin binding; IMP:CAFA.
DR   GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; TAS:Reactome.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0032880; P:regulation of protein localization; IDA:BHF-UCL.
DR   GO; GO:0009612; P:response to mechanical stimulus; IBA:GO_Central.
DR   GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0009411; P:response to UV; IDA:MGI.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:CAFA.
DR   IDEAL; IID00270; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008351; MAPK_JNK.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01772; JNKMAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Biological rhythms;
KW   Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; S-nitrosylation; Serine/threonine-protein kinase;
KW   Synapse; Transferase.
FT   CHAIN           1..427
FT                   /note="Mitogen-activated protein kinase 8"
FT                   /id="PRO_0000186262"
FT   DOMAIN          26..321
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          371..427
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           183..185
FT                   /note="TXY"
FT   COMPBIAS        381..414
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        151
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         32..40
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         55
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         116
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P49185"
FT   MOD_RES         183
FT                   /note="Phosphothreonine; by MAP2K7"
FT                   /evidence="ECO:0000269|PubMed:11062067"
FT   MOD_RES         185
FT                   /note="Phosphotyrosine; by MAP2K4"
FT                   /evidence="ECO:0000269|PubMed:11062067"
FT   MOD_RES         377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91Y86"
FT   VAR_SEQ         206..281
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_054554"
FT   VAR_SEQ         208
FT                   /note="L -> I (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_004831"
FT   VAR_SEQ         219..230
FT                   /note="VCHKILFPGRDY -> IKGGVLFPGTDH (in isoform 3 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_004832"
FT   VAR_SEQ         380..427
FT                   /note="GAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR ->
FT                   AQVQQ (in isoform 1, isoform 3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:19054851, ECO:0000303|Ref.3"
FT                   /id="VSP_004833"
FT   VARIANT         171
FT                   /note="G -> S (in a renal clear cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042258"
FT   VARIANT         177
FT                   /note="G -> R (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042259"
FT   VARIANT         365
FT                   /note="E -> K (in dbSNP:rs45483593)"
FT                   /id="VAR_050592"
FT   MUTAGEN         55
FT                   /note="K->D: Abolished protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:22966201"
FT   MUTAGEN         183
FT                   /note="T->A: Phosphorylation blocked."
FT                   /evidence="ECO:0000269|PubMed:7839144"
FT   MUTAGEN         185
FT                   /note="Y->F: Phosphorylation blocked."
FT                   /evidence="ECO:0000269|PubMed:7839144"
FT   HELIX           4..9
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          10..15
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          18..23
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          26..34
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          36..45
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   TURN            46..49
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          50..58
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           60..62
FT                   /evidence="ECO:0007829|PDB:4QTD"
FT   HELIX           64..79
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          83..85
FT                   /evidence="ECO:0007829|PDB:2GMX"
FT   STRAND          88..92
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          94..97
FT                   /evidence="ECO:0007829|PDB:3VUM"
FT   TURN            98..100
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          103..109
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          112..114
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           115..120
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           125..144
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           154..156
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   TURN            161..163
FT                   /evidence="ECO:0007829|PDB:2H96"
FT   STRAND          165..167
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   STRAND          174..177
FT                   /evidence="ECO:0007829|PDB:3O2M"
FT   STRAND          178..180
FT                   /evidence="ECO:0007829|PDB:2NO3"
FT   STRAND          182..184
FT                   /evidence="ECO:0007829|PDB:3ELJ"
FT   STRAND          185..187
FT                   /evidence="ECO:0007829|PDB:2G01"
FT   HELIX           189..191
FT                   /evidence="ECO:0007829|PDB:3PZE"
FT   HELIX           194..197
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           206..220
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           230..241
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           246..249
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           254..261
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           271..274
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           277..279
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           285..301
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           306..308
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           312..317
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           319..322
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           327..330
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   TURN            339..342
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   HELIX           349..363
FT                   /evidence="ECO:0007829|PDB:2XRW"
FT   MOD_RES         P45983-2:377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         P45983-3:377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         P45983-5:301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
SQ   SEQUENCE   427 AA;  48296 MW;  94FB6BE0358B9B60 CRC64;
     MSRSKRDNNF YSVEIGDSTF TVLKRYQNLK PIGSGAQGIV CAAYDAILER NVAIKKLSRP
     FQNQTHAKRA YRELVLMKCV NHKNIIGLLN VFTPQKSLEE FQDVYIVMEL MDANLCQVIQ
     MELDHERMSY LLYQMLCGIK HLHSAGIIHR DLKPSNIVVK SDCTLKILDF GLARTAGTSF
     MMTPYVVTRY YRAPEVILGM GYKENVDLWS VGCIMGEMVC HKILFPGRDY IDQWNKVIEQ
     LGTPCPEFMK KLQPTVRTYV ENRPKYAGYS FEKLFPDVLF PADSEHNKLK ASQARDLLSK
     MLVIDASKRI SVDEALQHPY INVWYDPSEA EAPPPKIPDK QLDEREHTIE EWKELIYKEV
     MDLEERTKNG VIRGQPSPLG AAVINGSQHP SSSSSVNDVS SMSTDPTLAS DTDSSLEAAA
     GPLGCCR
//
